Cancer drug tested in fight against COVID-19
NCT ID NCT04394416
Summary
This study tested whether adding the cancer drug imatinib to standard hospital care could help adults hospitalized with COVID-19. The goal was to see if the drug could reduce deaths by potentially blocking the virus and reducing severe lung inflammation. The trial was stopped early after enrolling only 21 patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Maryland Medical Center
Baltimore, Maryland, 21201, United States
Conditions
Explore the condition pages connected to this study.